AstraZeneca Scraps Volrustomig Trial as US Drug Prices Hit Sixty Year Lows

By Ed Silverman · STAT News · 2026-08-17

According to reporting from STAT News, AstraZeneca is ending a Phase 3 study for its metastatic lung cancer treatment after an independent monitor found the drug unlikely to improve patient survival. The setback for the pharmaceutical giant coincides with new federal data showing

According to reporting from STAT News, AstraZeneca is ending a Phase 3 study for its metastatic lung cancer treatment after an independent monitor found the drug unlikely to improve patient survival. The setback for the pharmaceutical giant coincides with new federal data showing